Cargando…
Su1480: TREATMENT-EMERGENT COVID-19 INFECTIONS IN OZANIMOD ULCERATIVE COLITIS AND MULTIPLE SCLEROSIS CLINICAL TRIALS
Autores principales: | Ungaro, Ryan C., Siegel, Corey A., Cree, Bruce, Selmaj, Krzysztof, Ahmad, Harris, Pai, Ashwini, Ather, Shabana, Henry, Alyssa, Charles, Lorna, Petersen, AnnKatrin, Cheng, Chun-Yen, Afsari, Sonia, Sheffield, James K., Vaile, John, Colombel, Jean Frederic |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AGA Institute. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212334/ http://dx.doi.org/10.1016/S0016-5085(22)61402-1 |
Ejemplares similares
-
Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
por: Dubinsky, Marla C., et al.
Publicado: (2022) -
Su1493: COVID-19 RELATED THROMBOTIC, CARDIOVASCULAR, AND RENAL COMPLICATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM AN INTERNATIONAL REGISTRY
por: Spiera, Emily, et al.
Publicado: (2022) -
Su1482: SCOUT IBD: SURVEILLANCE OF COVID-19 IMPACT ON LONG-TERM OUTCOMES IN IBD
por: Hong, Simon J., et al.
Publicado: (2022) -
Su1483: COVID-19 VACCINES ARE HIGHLY EFFECTIVE IN PATIENTS WITH IBD: OUTCOMES FROM THE SCOUT IBD COHORT
por: Hong, Simon J., et al.
Publicado: (2022) -
Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS
por: Grover, Shilpa, et al.
Publicado: (2020)